Company Overview and News

What's Next For Metals & Mining Companies?

2018-10-09 seekingalpha
Chinese economic sentiment peaked in Q1 of this year and is currently back at neutral levels.

2019 Economic Outlook: Deflationary Bust Led By China

2018-07-16 seekingalpha
The synchronized global growth experienced for the past 18 months has been driven by expansionary monetary policy in China.

Trump Renews Global Trade War Fears: ETF Winners & Losers

2018-06-01 zacks
President Donald Trump reignited fears of a trade war by imposing 25% tariff on steel imports and 10% on aluminum imports on America’s biggest allies — European Union, Canada and Mexico. These countries were previously exempted from the duties since its announcement in March. The current exemption will end on Jun 1 (read: Trump, Tariff & Geopolitics Lead May: 10 Top ETF Stories). The move has prompted retaliatory measures from its trading partners targeting American products worth billions of dollars.

Mining Stocks - Breakout Opportunity

2018-03-16 seekingalpha
Mining stocks (SPDR S&P Metals & Mining ETF (XME)) are breaking out of a multi-year downtrend. The breakout is fundamentally supported and could lift cyclical mining stocks even higher. The ETF I am discussing lets you benefit from this trend without exposing yourself to volatile single-company risks.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to XME / SPDR S&P Metals & Mining ETF on message board site Silicon Investor.

NEXM: NexMed, Inc. NEXM: NexMed, Inc. NEXM: NexMed, Inc. Nexmedia Technologies Inc (NXM) Nexmedia Technologies Inc (NXM) Nexmedia Technologies Inc (NXM)
CUSIP: 78464A755